Trial Profile

Safety and immunogenicity study of nivolumab with or without GS-4774 in patients with HBeAg negative chronic hepatitis B infection

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 16 Nov 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GS 4774 (Primary) ; Nivolumab (Primary)
Indications Hepatitis B
Focus Therapeutic Use

Most Recent Events

24 Oct 2017 Results assessing immunological aseessment presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases.
08 Jul 2017 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com